Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)
Close on Nov 17, 2026Market cap $110.85MP/E –Yield –
Atrium Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Atrium Therapeutics's price to book ratio was 0.6× on Nov 11, 2026.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.6× | – |
See a number that looks wrong?